SparingVision is a biotechnology company focused on the discovering and development of an innovative, therapeutic approach for treatment of blinding inherited retinal diseases such as retinitis pigmentosa.
People affected by Retinitis pigmentosa
People affected by RP in France
People affected by RP in the World
Mutations in more than 60 genes are known to cause RP
President SparingVison's Board of Directors - Managing Director for Lifesciences and Ecotechnology in Bpifrance Investissement.
"We are very proud to be investors of SparingVision. This new company is representing a real hope of treatment for the affected patients. We are confident on the high potential of the technology and on the level of the management for developing a very promising company"
Patricia Zilliox, Pharm D., PhD.
SparingVison's Board Directors - Chief Drug Development Officer for Foundation Fighting Blindness CRI
"We have been excited about this therapy’s potential for saving vision, and therefore committed significant resources to boost its development. The establishment of SparingVision and the investment by our partners are essential to getting the treatment into the marketplace. We are pleased to be a part of this translational process."
Jean Charles Pomerol
SparingVison's Board Director - President Fondation Voir & Entendre
"This therapeutic solution is the only one known to be able to slow down the evolution towards total blindness. We are very optimistic about the ability of SparingVision's teams to make this therapy a routine that will change the lives of millions of patients. This successful development also demonstrates the validity of our model "from bench to bedside", through the creation of innovative companies."
Prof José Alain Sahel, MD, PhD.
Founder - Director of Institut de la Vision
"Saving retinal cone cells is critical for preserving vision regarding people with genetic retinal diseases."
Thierry Léveillard, PhD.
Founder - Director of Department of Genetic - Institut de la Vision
“After several years of investigation, we understand the mechanism of action for RdCVF and have demonstrated its strong efficacy in several lab studies.”
Florence Allouche Ghrenassia, Pharm D.
“SparingVision’s emerging therapy has the potential to save the vision of millions. I am delighted to receive ILab 2017 Grand Prix for such a promising project and to be supported by our investors to get the therapy out to the people who desperately need it.”